A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress

Simply Wall St.04-30

AdvertisementWhy Teva’s latest earnings are back in focus Teva Pharmaceutical Industries (NYSE:TEVA) is back on investor radar after first quarter 2026 results. The company reported higher net income ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2631682954?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-04-30 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631682954","market":"sg","top_or_hot":-1,"title":"A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Teva’s latest earnings are back in focus Teva Pharmaceutical Industries (NYSE:TEVA) is back on investor radar after first quarter 2026 results. The company reported higher net income ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-teva-valuation-after-strong-q1-2026-earnings\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-30 17:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-teva-valuation-after-strong-q1-2026-earnings><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Teva’s latest earnings are back in focus Teva Pharmaceutical Industries (NYSE:TEVA) is back on investor radar after first quarter 2026 results. The company reported higher net income ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-teva-valuation-after-strong-q1-2026-earnings\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-teva-valuation-after-strong-q1-2026-earnings","article_id":"2631682954","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/a-look-at-teva-teva-valuation-after-strong-q1-2026-earnings","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2631682954","pubTimestamp":1777540258,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Teva’s latest earnings are back in focus\nTeva Pharmaceutical Industries (NYSE:TEVA) is back on investor radar after first quarter 2026 results. The company reported higher net income and operating income, provided fresh biosimilar updates, and highlighted stronger UZEDY sales alongside a new schizophrenia NDA filing.\nSee our latest analysis for Teva Pharmaceutical Industries.\nThe strong first quarter update, FDA progress for biosimilars, and Emalex deal have come alongside sharp gains,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药","PRGS":"Progress Software Corporation"},"translate_title":"在2026年第一季度强劲盈利和生物仿制药管道进展之后，看看梯瓦(TEVA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"PRGS":1.5},"content_text":"AdvertisementWhy Teva’s latest earnings are back in focus Teva Pharmaceutical Industries (NYSE:TEVA) is back on investor radar after first quarter 2026 results. The company reported higher net income and operating income, provided fresh biosimilar updates, and highlighted stronger UZEDY sales alongside a new schizophrenia NDA filing. See our latest analysis for Teva Pharmaceutical Industries. The strong first quarter update, FDA progress for biosimilars, and Emalex deal have come alongside sharp gains, with a 24.8% 30 day share price return and a very large 3 year total shareholder return that signals momentum building rather than fading. If you are looking beyond large pharma to see where the next set of growth stories could emerge, this is a good moment to scan 32 healthcare AI stocks After a 128.1% 1 year total return, a 3x 3 year total shareholder return, and a share price that now sits near analyst targets while screens still flag a value gap, is Teva underpriced, or is the market already banking on future growth? Most Popular Narrative: 7.3% Undervalued Teva’s most followed narrative pegs fair value at $38.18 per share, a touch above the latest close at $35.38, and ties that gap directly to future earnings power and margin assumptions.  The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.  Read the complete narrative. Curious what holds that fair value together? The narrative leans heavily on modest revenue growth, rising profitability, and a richer earnings multiple that still sits above the sector. The full set of assumptions shows how those moving parts connect to a specific long term earnings level and a premium P/E that needs to hold for the story to work. Result: Fair Value of $38.18 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the heavy reliance on a few branded drugs and a net debt load above US$15b, which could limit the company’s flexibility in the future. Find out about the key risks to this Teva Pharmaceutical Industries narrative. Another way to look at Teva’s valuation The earlier fair value view leans on future earnings and margins. By contrast, today’s $35.38 price implies a P/E of 29.2x, which is higher than both the US Pharmaceuticals average at 15.8x and Teva’s own fair ratio of 22.1x, so the multiple already bakes in a lot of optimism. If earnings or sentiment cool, how far could that P/E realistically drift toward the fair ratio? See what the numbers say about this price — find out in our valuation breakdown. NYSE:TEVA P/E Ratio as at Apr 2026Next Steps Seeing both optimism and concern around Teva, it may be helpful to move quickly and review the evidence yourself, starting with the 3 key rewards and 2 important warning signs Looking for more investment ideas? If Teva has caught your attention, do not stop here, some of the most interesting opportunities often sit just outside your current watchlist.  Spot companies with strong cash generation and appealing valuations by scanning the 53 high quality undervalued stocks. Prioritize resilience and capital preservation by reviewing the 73 resilient stocks with low risk scores. Hunt for underfollowed names with solid fundamentals using the screener containing 25 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631682954","isCrawlerRequest":true}